Ewing Sarcoma is an aggressive malignancy of bone and soft tissue affecting children and young adults. Ewing Sarcoma is driven by EWS/Ets fusion oncoproteins, which cause widespread alterations in gene expression in the cell. Dysregulation of receptor tyrosine kinase signaling, particularly involving IGF-1R, also plays an important role in Ewing Sarcoma pathogenesis. However, the basis of this ...

Ewing sarcoma is an aggressive pediatric cancer of the bone and soft tissue, in which patients whose tumors have a poor histologic response to initial chemotherapy have a poor overall prognosis. Therefore, it is important to identify molecules involved in resistance to chemotherapy. Herein, we show that the DNA repair protein and transcriptional cofactor, EYA3, is highly expressed in Ewing sarc...

Ewing sarcoma is an aggressive pediatric cancer of the bone and soft tissue, in which patients whose tumors have a poor histologic response to initial chemotherapy have a poor overall prognosis. Therefore, it is important to identify molecules involved in resistance to chemotherapy.Herein, we show that theDNA repair protein and transcriptional cofactor, EYA3, is highly expressed in Ewing sarcom...

primary bone tumors are the sixth most common neoplasm occurring in children and constitute approximately 6% of all childhood malignancies with a peak incidence in 15- to 19-year- old individuals. these lesions are the third most common tumors in adolescents and young adults (exceeded only by leukemia and lymphoma) common complaints are intermittent to constant mild to severe pain, constitution...

treatment with intensification of chemotherapy using alkylating agents and topoisomerase ii inhibitors and radiotherapy has improved the outcome of patients with solid tumors such as ewing’s sarcoma. however, there are several reports of secondary malignancy following treatment of these tumors. in this article, we describe a 12 years old girl with all who had ewing’s sarcoma when she was 8 year...

Limited progress has been made in the treatment of advanced-stage pediatric solid tumors despite the accelerated pace of cancer discovery over the last decade. Tyrosine kinase inhibition is one tractable therapeutic modality for treating human malignancy. However, little is known about the kinases critical to the development or maintenance of many pediatric solid tumors such as Ewing sarcoma. U...

The EWS/FLI translocation product is the causative oncogene in Ewing sarcoma and acts as an aberrant transcription factor. EWS/FLI dysregulates gene expression during tumorigenesis by abnormally activating or repressing genes. The expression levels of thousands of genes are affected in Ewing sarcoma, however, it is unknown which of these genes contribute to the transformed phenotype. Here we ch...

Interleukin-2 (IL-2) transgenic Ewing sarcoma cells can induce tumor specific T and NK cell responses and reduce tumor growth in vivo and in vitro. Nevertheless, the efficiency of this stimulation is not high enough to inhibit tumor growth completely. In addition to recognition of the cognate antigen, optimal T-cell stimulation requires signals from so-called co-stimulatory molecules. Several m...

background: primary malignant bone tumors are heterogeneous groups of neoplasms, which affect mainly children and adolescents. the most common types are osteosarcoma, ewing sarcoma and chondrosarcoma. elevation of scd30 and scd40l has been observed in lymphoma, leukemia and autoimmune disorders. objective: to evaluate serum concentrations of scd30 and scd40l in patients with primary malignant b...

PURPOSE Although mutations in the TP53 gene occur in half of all cancers, approximately 90% of Ewing sarcomas retain a functional wild-type p53. The low frequency of TP53 alterations in Ewing sarcoma makes this tumor type an ideal candidate for p53-targeted therapies. In this study, we have examined the molecular and cellular responses of cultured Ewing sarcoma cell lines following exposure to ...